Aura Biosciences, Inc. Other Nonoperating Income (Expense)
Aura Biosciences, Inc. (AURA) reported Other Nonoperating Income (Expense) of $154.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-11
- Aura Biosciences, Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was $154.00K.
- Aura Biosciences, Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was $2.00K.
- Aura Biosciences, Inc. other nonoperating income (expense) for the quarter ending 2025-12-31 was $149.00K.
- Aura Biosciences, Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was -$13.00K.
- Aura Biosciences, Inc. other nonoperating income (expense) for fiscal 2025 was $77.00K.
- Aura Biosciences, Inc. other nonoperating income (expense) for fiscal 2024 was -$120.00K.
- Aura Biosciences, Inc. other nonoperating income (expense) for fiscal 2023 was -$76.00K.
- Aura Biosciences, Inc. other nonoperating income (expense) for fiscal 2022 was -$14.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 3 month as first filed | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 9 month as first filed | Other Nonoperating Income (Expense) 12 month | Other Nonoperating Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $154.00K 10-Q · filed 2026-08-11 | $155.00K 10-Q · filed 2026-08-11 | $305.00K derived: sum of 3 quarters · filed 2026-08-11 | $292.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $2.00K 10-Q · filed 2026-05-11 | $151.00K derived: sum of 2 quarters · filed 2026-05-11 | $138.00K derived: sum of 3 quarters · filed 2026-05-11 | $102.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $136.00K derived: sum of 2 quarters · filed 2026-03-30 | $100.00K derived: sum of 3 quarters · filed 2026-08-11 | $77.00K 10-K · filed 2026-03-30 | |||
| 2025-09-30 | -$13.00K 10-Q · filed 2025-11-13 | -$49.00K derived: sum of 2 quarters · filed 2026-08-11 | -$72.00K 10-Q · filed 2025-11-13 | -$110.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | -$36.00K 10-Q · filed 2026-08-11 | -$59.00K 10-Q · filed 2026-08-11 | -$97.00K derived: sum of 3 quarters · filed 2026-08-11 | -$122.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | -$24.00K 10-Q · filed 2026-05-11 | -$61.00K derived: sum of 2 quarters · filed 2026-05-11 | -$86.00K derived: sum of 3 quarters · filed 2026-05-11 | -$112.00K derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | -$37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$62.00K derived: sum of 2 quarters · filed 2026-03-30 | -$88.00K derived: sum of 3 quarters · filed 2026-03-30 | -$120.00K 10-K · filed 2026-03-30 | |||
| 2024-09-30 | -$25.00K 10-Q · filed 2025-11-13 | -$51.00K derived: sum of 2 quarters · filed 2025-11-13 | -$83.00K 10-Q · filed 2025-11-13 | -$109.00K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$26.00K 10-Q · filed 2025-08-13 | -$57.00K 10-Q · filed 2025-08-13 | -$84.00K derived: sum of 3 quarters · filed 2025-08-13 | -$89.00K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | -$32.00K 10-Q · filed 2025-05-15 | -$58.00K derived: sum of 2 quarters · filed 2025-05-15 | -$63.00K derived: sum of 3 quarters · filed 2025-05-15 | -$95.00K derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$31.00K derived: sum of 2 quarters · filed 2025-03-24 | -$63.00K derived: sum of 3 quarters · filed 2025-03-24 | -$76.00K 10-K · filed 2025-03-24 | |||
| 2023-09-30 | -$5.00K 10-Q · filed 2024-11-12 | -$37.00K derived: sum of 2 quarters · filed 2024-11-12 | -$50.00K 10-Q · filed 2024-11-12 | $260.00K derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | -$32.00K 10-Q · filed 2024-08-08 | -$45.00K 10-Q · filed 2024-08-08 | $265.00K derived: sum of 3 quarters · filed 2024-08-08 | -$64.00K derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | -$13.00K 10-Q · filed 2024-05-09 | $297.00K derived: sum of 2 quarters · filed 2024-05-09 | -$32.00K derived: sum of 3 quarters · filed 2024-05-09 | $24.00K derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $310.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$19.00K derived: sum of 2 quarters · filed 2024-03-27 | $37.00K derived: sum of 3 quarters · filed 2024-03-27 | -$14.00K 10-K · filed 2024-03-27 | -$5.00K 10-K · filed 2023-03-15 | ||
| 2022-09-30 | -$329.00K 10-Q · filed 2023-11-09 | -$7.00K 10-Q · filed 2022-11-10 | -$273.00K derived: sum of 2 quarters · filed 2023-11-09 | -$324.00K 10-Q · filed 2023-11-09 | $3.00K 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $56.00K 10-Q · filed 2023-08-09 | $5.00K 10-Q · filed 2023-08-09 | |||||
| 2022-03-31 | -$44.00K 10-Q · filed 2023-05-11 | ||||||
| 2021-09-30 | $52.00K 10-Q · filed 2022-11-10 | $1.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |